Celldex Therapeutics, Inc. (CLDX) Stock
4 of the hedge funds AlphaScala tracks reported CLDX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $43.56M.
Which hedge funds own CLDX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 1.17M | $43.56M | -7% |
| Point72 Steve Cohen | 117K | $4.36M | -96% |
| D.E. Shaw David Shaw | 18K | $663.3K | -66% |
| Blackstone | 6K | $239.6K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →CLDX price chart
Powered by TradingViewWhat does Celldex Therapeutics, Inc. do?
Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted immunotherapies for cancer and other serious diseases. Its research platforms leverage novel antibody therapeutics, antibody-drug conjugates, and immune-activating agents designed to engage the patient's immune system and deliver precise cytotoxic activity. Key product candidates include barzolvolimab, an investigational monoclonal antibody targeting KIT for chronic spontaneous urticaria and other mast cell-mediated disorders; glembatumumab vedotin, an antibody-drug conjugate against glycoprotein NMB for certain breast and skin cancers; varlilumab, an agonist antibody targeting CD27 to enhance immune responses; CDX-301, a recombinant human Flt3 ligand to expand dendritic and immune cell populations; CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells; and CDX-0159, part of the anti-KIT program. Celldex Therapeutics Inc. advances these programs through clinical trials in oncology, neurology, and inflammatory diseases, primarily serving patients in North America via collaborations with academic centers and industry partners. Founded in 1983 and headquartered in Hampton, New Jersey, it plays a vital role in the biotechnology sector by pioneering next-generation immunotherapies.